Molecular Templates' NHL candidate shows higher response rates with low baseline Rituxan levels

Molecular Templates Inc. (NASDAQ:MTEM) reported Phase I data from 10 evaluable relapsed or refractory diffuse large B cell lymphoma (DLBCL) patients with

Read the full 227 word article

User Sign In